Figure 5
From: Suppression of endothelial cell activity by inhibition of TNFα
Certolizumab pegol inhibits TNFα-induced human dermal microvascular endothelial cell chemotaxis. (A) Increasing concentrations of TNFα induce human dermal microvascular endothelial cell (HMVEC) migration, which is significant from concentrations of 0.1 to 250 ng/ml, compared with PBS control (*P < 0.05). (B) Certolizumab pegol (1 to 100 μg/ml) decreased TNFα-induced HMVEC migration (from 69% to 89%) when HMVECs were preincubated with different concentrations of certolizumab pegol (*P < 0.05). Cell migration per three high-power fields (3HPF; ×400) was determined by the number of HMVECs migrated towards an angiogenic stimulus. Results represent the mean number of migrating cells per each quadruplicate well ± standard error of the mean. n, number of individual experiments. The positive control was basic fibroblast growth factor (bFGF; 60 nM) and PBS was the negative control.